Clinical Trial PRECOGHEM0901


Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Principal Investigator(s)

Stephen Strickland


  • Protocol No. PRECOGHEM0901
  • Open Date: 12/04/2012
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the safety, tolerability and optimal dose of eltrombopag in acute myeloid leukemia patients in complete remission receiving intensive consolidation chemotherapy.
  • Disease Sites: Leukemia
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cytarabine (ARA-C); Eltrombopag
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01656252
  • Secondary Protocol No: Not Specified